Stock-Based Compensation

12 Months Ended

Dec. 31, 2025

Share-Based Payment Arrangement [Abstract]

Stock-Based Compensation

20)STOCK-BASED COMPENSATION

We account for stock-based compensation under the fair value recognition provisions of ASC Topic 718 - Compensation - Stock Compensation. We recognize stock-based compensation cost over the award’s requisite service period on a straight-line basis for time-based restricted stock grants and performance-based restricted stock grants. We record forfeitures as they occur for all stock-based compensation.

Under the Company’s 2013 Omnibus Incentive Plan, 1,000,000 shares were authorized for issuance at December 31, 2020. In 2020, the Board of Directors adopted the 2020 Omnibus Incentive Plan, which was approved by shareholders during our 2020 Annual Meeting of Stockholders. At the time of approval, an additional 2,000,000 shares were authorized for issuance. In 2024, the 2020 Omnibus Incentive Plan was amended and approved by shareholders during the 2024 Annual Meeting of Stockholders, authorizing an additional 2,000,000 shares for issuance.

The following table presents our total stock-based compensation expense:

	Year Ended December 31,
	2025		2024		2023
Employee stock-based compensation expense
Pre-tax (1)	$	3,798	$	2,097	$	1,082
Post-tax (2)		3,000		1,657		855
Director stock-based compensation expense
Pre-tax (1)		501		448		174
Post-tax (2)		396		354		137

(1) This table does not include withholding of vested shares for tax liabilities, which totaled $1,855,000, $1,359,000 and $24,000 in 2025, 2024, and 2023, respectively.

(2) The after-tax amounts are determined using the 21% corporate federal tax rate.

We had approximately $3,887,000 of unrecognized stock compensation expense at December 31, 2025 related to non-vested stock-based compensation granted, which we expect to recognize over a weighted-average period of approximately 1.8 years. We had approximately $183,000 of unrecognized director stock-based compensation expense at December 31, 2025, related to non-vested director stock-based compensation granted, which we expect to recognize over a weighted-average period of approximately 0.4 years.

Restricted stock, restricted stock units and performance stock units

Stock-based compensation cost for restricted stock awards, restricted stock units and performance stock units is measured based on the closing fair market value of our common stock on the date of grant, which vest in equal installments over the requisite service period of typically three years. Restricted stock awards granted to non-employee directors vest over a one-year period. Each restricted stock unit and performance stock unit represents our obligation to deliver to the holder one share of common stock upon vesting.

Performance stock units vest based on the Company’s return on average equity compared to a defined group of peer companies. On the grant date, we issue the target number of performance stock units. They are subject to forfeitures if performance goals are not met. The actual number of performance stock units earned can vary from zero to 150 percent of the target for the 2025, 2024, and 2023 awards.

We granted 466,672, 598,713 and 45,000 shares of restricted common stock, which had a weighted-average grant date fair value of $11.48, $7.41 and $5.25 per share during the years ended December 31, 2025, 2024, and 2023, respectively. Additionally, during the year ended December 31, 2023, the Company granted 262,933 shares of restricted common stock, with a fair value of $4.33 per share, which were contingent upon stockholder approval of an increase in the number of shares of our common stock that may be issued pursuant to the 2020 Omnibus Incentive Plan. This increase was approved during our 2024 Annual Meeting of Shareholders and the impact of the contingent grants is included in the granted shares described above and seen in the table below.

The following table presents certain information related to the activity of our non-vested common stock grants:

	Number of Restricted Shares		Weighted Average Grant Date Fair Value
Outstanding as of December 31, 2022		714,239	$	2.73
Granted		45,000		5.25
Less: Forfeited		132,259		3.16
Less: Vested		181,334		3.25
Outstanding as of December 31, 2023		445,646	$	2.64
Granted (1)		598,713		7.41
Less: Forfeited		1,476		4.56
Less: Vested		436,472		3.36
Outstanding as of December 31, 2024		606,411	$	6.23
Granted		466,672		11.48
Less: Forfeited		1,509		11.51
Less: Vested		494,793		5.29
Outstanding as of December 31, 2025		576,781	$	10.12

(1) Contingent shares granted during 2023 have been included in the calculation of 2024’s granted values.

Stock options

Stock option fair value was estimated on the grant date using the Black-Scholes-Merton formula. Stock options vest in equal installments over the requisite service period of typically three years. The following weighted-average assumptions were used to value the stock options granted:

	2025			2024
Expected annual dividend yield		—	%		—	%
Expected volatility		88.51	%		86.92	%
Risk-free interest rate		3.87	%		4.37	%
Expected term	6 years			6 years

The expected annual dividend yield for our options granted during 2025 and 2024 is based on no dividends being paid in future quarters. The expected volatility is a historical volatility calculated based on the daily closing prices over a period equal to the expected term. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the grant date. Expected term takes into account the three-year graded vesting term and the 10-year contractual term of the option.

We granted 76,141 stock options during the year ended December 31, 2025, which had a weighted average grant date fair value of $11.63 per share. We granted 196,275 stock options for the year ended December 31, 2024, which had a weighted average grant date fair value of $7.77 per share. We did not grant any stock options during the year ended December 31, 2023, however, during the year ended December 31, 2023, the Company granted 123,399 stock options, with a fair value of $3.08, which were contingent upon stockholder approval of an increase in the number of shares of our common stock that may be issued pursuant to the 2020 Omnibus Incentive Plan. This increase was approved during our 2024 Annual Meeting of Stockholders and the impact of the contingent grants is included in the granted options described above and seen in the table below.

The following table presents certain information related to the activity of our non-vested stock option grants:

	Number of Stock Options		Weighted Average Exercise Prices		Weighted Average Remaining Contractual Term (years)		Aggregate Intrinsic Value (1)
Outstanding as of December 31, 2022		1,250,685	$	3.71		7.66	$	—
Granted		—		—		—		—
Less: Forfeited		40,000		3.46		—		—
Less: Expired		161,925		3.05		—		—
Less: Exercised		20,000		3.46		—		—
Outstanding as of December 31, 2023		1,028,760	$	3.83		7.80	$	6,151,000
Vested and Exercisable as of December 31, 2023		580,568	$	4.78		7.56	$	3,071,000
Outstanding as of December 31, 2023		1,028,760	$	3.83		7.80	$	6,151,000
Granted (2)		196,275		4.82		—		—
Less: Forfeited		—		—		—		—
Less: Expired		—		—		—		—
Less: Exercised		95,000		2.35		—		—
Outstanding as of December 31, 2024		1,130,035	$	4.12		7.21	$	10,202,000
Vested and Exercisable as of December 31, 2024		840,768	$	4.30		6.79	$	7,501,000
Outstanding as of December 31, 2024		1,130,035	$	4.12		7.21	$	10,202,000
Granted		76,141		11.63		—		—
Less: Forfeited		—		—		—		—
Less: Expired		—		—		—		—
Less: Exercised		240,446		3.17		—		—
Outstanding as of December 31, 2025		965,730	$	4.95		6.50	$	6,949,000
Vested and Exercisable as of December 31, 2025		799,869	$	4.24		6.02	$	6,368,000

(1) Presented in ones.

(2) Contingent shares granted as of December 31, 2023 have been included in the calculation of granted values as of December 31, 2024.